MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
OriCell Therapeutics
Attachments
OriCell Therapeutics-Committed to developing novel immunotherapies
Parents
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Immuno-Oncology, Immunotherapy
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Industry: China
Venture Capital: Series B
Children
**Its platform combines three proprietary technologies: Ori®Ab for antibody discovery and engineering, Ori®Armoring for functional T-cell enhancement, and OnGo CMC for rapid manufacturing.
*Oricell is developing next-generation CAR-T therapies targeting both solid tumors and hematologic malignancies
2023: $120 million in Series B cash in a round led by Qiming Venture Partners and Quan Capital, RTW Investments and Qatar Investment Authority.
2026: Oricell Therapeutics: $110 Million Pre-IPO Financing To Advance Solid Tumor CAR-T Pipeline
2026: The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. Additional participants included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
Founded 2015